Truist Financial Corp Sells 2,471 Shares of Amicus Therapeutics, Inc. $FOLD

Truist Financial Corp lessened its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,520 shares of the biopharmaceutical company’s stock after selling 2,471 shares during the quarter. Truist Financial Corp’s holdings in Amicus Therapeutics were worth $129,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Diversified Trust Co increased its holdings in Amicus Therapeutics by 2.2% in the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company’s stock valued at $682,000 after purchasing an additional 1,784 shares during the last quarter. Tempus Wealth Planning LLC grew its stake in Amicus Therapeutics by 7.2% in the first quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 1,990 shares during the period. Stephens Inc. AR grew its stake in Amicus Therapeutics by 27.4% in the first quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 2,938 shares during the period. PNC Financial Services Group Inc. grew its stake in Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 3,497 shares during the period. Finally, Strs Ohio acquired a new position in Amicus Therapeutics in the first quarter valued at about $30,000.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Finally, Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Amicus Therapeutics has an average rating of “Moderate Buy” and an average target price of $15.88.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $8.04 on Friday. The stock has a 50 day moving average price of $7.88 and a 200 day moving average price of $6.89. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The stock has a market capitalization of $2.48 billion, a PE ratio of -66.99 and a beta of 0.56.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.